AbD Serotec and Thermo Fisher Scientific Sign Technology Agreement
Feb 12, 2007
AbD Serotec Customer Update
Martinsried/Munich, Germany, and Rockford, IL, U.S.A., February 12, 2007
AbD Serotec to sell fluorescent reagents developed using DyLight™ Technology
AbD Serotec – A division of MorphoSys of Munich, Germany, and Thermo Fisher Scientific Inc., the world leader in serving science, today announced the signing of an agreementcovering the use Thermo Scientific DyLight Dyes in combination with AbD Serotec’s research antibodies to prepare a series of fluorescent reagents. The resulting products will be available through the AbD Serotec sales catalogue. Financial details were not disclosed. DyLight Fluorescent Dyes, available exclusively as part of Thermo Scientific’s protein research product line, are an excellent alternative to other commercially available fluorescent dyes. DyLight Dyes are water-soluble and provide high fluorescence intensity in many applications, while maintaining excellent photostability across a broad range of pH values. DyLight Dyes are available over a wide range of spectra and match the output wavelengths of common fluorescence instrumentation.
AbD Serotec’s comprehensive product catalog comprises more than 10,000 research antibodies and immunology reagents guaranteed to perform to specification. Additionally, custom monoclonal antibodies are generated for non-therapeutic applications using the HuCAL technology. The HuCAL technology allows novel antibodies to be generated significantly faster than the current market standard and provides various other advantages over the use of animals for antibody production.
“Fluorescent antibodies are particularly suited for detection of specific antigens in tissues or on cells and have become an indispensable tool for scientists worldwide,” comments Dr.Achim Knappik Senior Director of R&D at AbD Serotec. “Combining the vast range of research antibodies offered by AbD Serotec with DyLight fluorescence technology enables AbD Serotec to further expand its wide range of fluorescent reagents, and will thus further enhance our offering in this segment.”
“DyLight Technology provides researchers a series of dyes with high fluorescence intensity and compatibility with instrumentation,” said Gary Shiels, Ph.D., director of marketing for Thermo Scientific Pierce protein-analysis products. “We are pleased AbD Serotec has selected the DyLight Technology to prepare fluorescent labels for its wide range of antibodies, further enabling the use of DyLight Technology in a wide range of applications.”
About MorphoSys’ AbD Serotec:
MorphoSys develops and applies innovative technologies for the production of synthetic antibodies which accelerate drug discovery and target characterization. Founded in 1992, the Company’s proprietary Human Combinatorial Antibody Library (HuCAL®) technology is used by researchers worldwide for human antibody generation. The Company currently has licensing and research collaborations with Bayer (Berkeley, California/USA), Boehringer Ingelheim (Ingelheim, Germany), Bristol-Myers Squibb (New Jersey/USA), Centocor Inc. (Malvern, Pennsylvania/USA), Daiichi Sankyo & Co., Ltd. (Tokyo/Japan), GPC Biotech AG (Munich/Germany), Hoffmann-La Roche AG (Basel/Switzerland), ImmunoGen Inc. (Cambridge, Massachusetts/USA), Merck & Co., Inc. (Whitehouse Station, New Jersey/USA), Novartis AG (Basel, Switzerland), Novoplant GmbH (Gatersleben, Germany), OncoMed Pharmaceuticals Inc. (Mountain View, C USA), Pfizer Inc. (Delaware/USA), ProChon Biotech Ltd. (Rehovot/Israel), Schering AG (Berlin/Germany), Schering-Plough (Palo Alto/USA), Shionogi & Co., Ltd. (Osaka/Japan), Xoma Ltd. (Berkeley, California/USA) and others.
Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit. For further information, please visit the corporate website at: http://www.morphosys.com; information on MorphoSys ’s AbD Serotec is available at: http://www.ab-direct.com.
About Thermo Fisher Scientific:
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With annual sales of more than $9 billion, we employ 30,000 people and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit www.thermofisher.com
Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, “forward-looking statements” for purposes of the safe harbour provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company’s future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company’s proprietary rights and other factors described in the prospectus relating to the company’s recent public offering.
For more information, please contact to AbD Serotec:
Business Development queries:
Dieter Lingelbach
Senior Vice President
AbD Serotec / MorphoSys
Lena-Christ Str. 48
82152 Martinsried / Planegg
Tel: +49 (0) 89 899 27 -234
Fax: +49 (0) 89 899 27 -5234
antibodies@ab-direct.com
www.ab-direct.com
Press and Investor queries:
Dave Lemus
MorphoSys AG
Chief Financial Officer
Tel: +49 (0) 89 899 27 -439
Fax: +49 (0) 89 899 27 -5439
investors@morphosys.com
www.morphosys.com
